ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

Vaccinated US nurse contracts COVID-19: ABC report

Expert says Pfizer shot needed more time to work

Pfizer "will review all available information on this case and all reports of any confirmed diagnosis following vaccination," the drug maker said in a statement to Reuters.    © Reuters

A nurse in California tested positive for COVID-19 more than a week after receiving Pfizer Inc's vaccine, an ABC News affiliate reported on Tuesday, but a medical expert and the U.S. drug maker said the body needs more time to build up protection.

Pfizer "will review all available information on this case and all reports of any confirmed diagnosis following vaccination," the drug maker said in a statement to Reuters.

"Based on our Phase 3 safety and efficacy study, the vaccine provides some protection against COVID-19 within about 10 days of the first dose and substantially boosted after the second dose, supporting the need for a 2-dose vaccination series", it said.

"Individuals may have contracted disease prior to or right after vaccination", the statement added.

Matthew W., 45, a nurse at two different local hospitals, said in a Facebook post on December 18 that he had received the Pfizer vaccine, telling the ABC News affiliate that his arm was sore for a day but that he had suffered no other side-effects.

Six days later on Christmas Eve, he became sick after working a shift in the COVID-19 unit, the report added. He got the chills and later came down with muscle aches and fatigue.

He went to a drive-up hospital testing site and tested positive for COVID-19 the day after Christmas, the report said.

Christian Ramers, an infectious disease specialist with Family Health Centers of San Diego, told the ABC News affiliate that this scenario was not unexpected.

"We know from the vaccine clinical trials that it's going to take about 10 to 14 days for you to start to develop protection from the vaccine," Ramers said. "That first dose we think gives you somewhere around 50%, and you need that second dose to get up to 95%."

(Reuters)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more